Acute graft-versus-host disease (aGVHD) is a major concern in stem cell transplantation and is associated with significant morbidity and mortality. 1, 2 We report a successful use of infusion of autologous peripheral blood stem cells (ASC) to treat severe, refractory grade 4 aGVHD after a nonmyeloablative matched unrelated donor (MUD) transplant. A 55-year-old white female presented in December 2000 with pain and pathological fracture of the left humerus and was diagnosed with multiple myeloma. Her bone marrow biopsy revealed 100% cellularity with 60% abnormal plasma cells, which were kappa light chain restricted. Cytogenetic studies revealed normal chromosomes. She had low immunoglobulins and serum M-spike of 0.1 gm/dl, and no Bence-Jones protein in the urine. Skeletal survey and CT scans of the chest, abdomen and pelvis showed diffuse multiple boney lytic lesions. Beta 2-microglobulin was 1.67 mg/dl. The patient was initially treated with one cycle of melphalan and prednisone while receiving radiation therapy. Subsequently, she received four cycles of VAD and one cycle of hyper-CVAD before receiving autologous stem cell transplantation (ASCT) in June 2001. She also received monthly infusion of pamidronate. Disease evaluation at 6 weeks post-ASCT showed progression of the disease. She then received a series of salvage therapies including 4 months of thalidomide, thalidomide and oral melphalan, palliative XRT for a new lumbosacral lesion, and three cycles of chemotherapy with lomustine, etoposide, cyclophosphamide, and prednisone, but all with transient or minimal response. She then underwent a nonmyeloablative MUD transplant on 07/10/ 02. Her conditioning regimen consisted of Fludarabine, ATGAM (horse antithymocyte globulin (ATG)), and busulfan. The fludarabine was given at 30 mg/m 2 /day on day À7 through day À2, ATGAM at 10 mg/kg/day on days À6 through day À3, and busulfan dose was 8 mg/kg in eight divided doses q 6 h. FK-506 was started on day À1 at 3 mg p.o. b.i.d. for GVHD prophylaxis.
Day þ 30 bone marrow biopsy revealed progression of her disease with 50-60% atypical plasma cells in the marrow and 91% male donor chimerism by interphase FISH analysis. Due to progression of disease, her FK 506 was tapered and discontinued on day þ 52. Her repeat chimerism studies on day 60 showed 87% donor. After a week of cessation of immunosuppressive therapy she developed grade 3 aGVHD involving skin and gut. She was admitted and restarted on FK 506 and intravenous solumedrol 2 mg/kg/day on day þ 63. Her aGVHD did not respond to steroids and she developed severe diarrhea, malabsorption, nausea and vomiting, abdominal pain, and eventually gastrointestinal bleeding. Her condition continued to deteriorate despite the addition of mycophenolate mofetil (MMF) 1 gm q 8 h, with diarrhea of 2.3 l/day and melena (grade 4 aGVHD). She was started on total intravenous parenteral nutrition (TPN). Other drugs were added, such as daclizumab, thalidomide, and remicade, without much improvement, prompting orders of 'do not resuscitate'. Her serum albumin dropped from 3.9 to 1.6 g/dl. At this point it was decided to give her chemotherapy with infusion of ASC (which were collected initially as part of the plans for tandem ASCT). She was given intravenous cyclophosphamide 300 mg/m 2 BID Â 2 days followed by infusion of ASC (10. 7 /kg CD3 þ cells) (see Figure 1 ). At this point she had 99.5% donor chimerism. Her symptoms started improving slowly and, after another 5 weeks of hospitalization and continued TPN, she was discharged from hospital on day þ 153. She is now over 2.5 years after her transplant. Her most recent disease evaluation showed very good partial remission (5% plasma cells in BM) with 100% donor chimerism. She is back to work and she has been off all immunosuppression except for short periods of treatment with steroids for upper respiratory symptoms, with bronchial spasm attributed to limited chronic GVHD.
The incidence of grade II-IV acute GVHD is 78% and grade III-IV is 24% after HLA MUD transplant. 3 Corticosteroids are the mainstay of therapy for aGVHD. Unfortunately, the rate of achieving a durable response with steroids is about 50%. 4 The outcome of those developing steroid-refractory disease is poor, with 60-80% dying from GVHD-related causes. 1 Commonly used salvage agents include ATG, MMF, sirolimus, PUVA, and Daclizumab.
We report a case of steroid-refractory GVHD, which did not respond to multiple known anti-GVHD therapies, successfully treated with chemotherapy and autologous stem cell infusion. A similar case was previously reported by Ricordi 5 who reported reversal of steroid-refractory cutaneous GVHD following combined liver-bone marrow allo-transplant by infusion of stored recipient autologous bone marrow. Passweg et al 6 have recently reported eight patients (seven aGVHD and one cGVHD) after allogeneic HSCT, who failed a median of four lines of therapy and were then treated with a 'rescue' transplant using autologous cells or syngeneic donor cells with the aim of improving the severe refractory GVHD. In four of five patients who received some form of conditioning before autologous cell infusion, mixed chimerism or complete recipient hematopoiesis was restored with a resolution of GVHD in four patients. Three patients obtained no benefit. Another report 7 described 'pseudoautologous' blood stem cell transplantation for the treatment of refractory cGVHD in a patient who had sibling allogeneic BMT for the treatment of acute leukemia. In this case, the therapeutic approach was similar to treatment of autoimmune diseases with autologous SCT. The cGVHD did improve; however, the patient died of relapse nine months later. In our case, our initial aim was to kill donor cells with cyclophosphamide and restore recipient hematopoiesis with infusion of autologous stem cells originally collected for planned tandem ASCT, hoping to achieve control of potentially lethal GVHD. However, after two autologous cell infusions, improvement of GVHD happened while maintaining donor chimerism. Such an outcome could be only explained by real tolerance developed between the recipient and donor and without inhibiting the graft-versusmyeloma effect or losing the donor chimerism. Multiple mechanisms for such induction of tolerance have been proposed by different investigators. These include downregulation of antihost reactivity by host veto cells, 8 donor T-cell anergy induced by recipient dendritic cell precursors type 2 (pDC2), 9 and induction of regulatory T cells. 10 In summary, we describe a case of successful treatment of steroid refractory GVHD with autologous PBSCT. This strategy needs to be further investigated in a prospective multi-center trial.
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